
Wall Street's rally stalls as US stocks post their 1st loss in 4 days
NEW YORK (AP) — Wall Street's rally stalled after stocks climbed back within 2% of their all-time high. The S&P 500 slipped 0.3% Wednesday, marking its first drop in four days. The Dow Jones Industrial Average ended little changed, and the Nasdaq composite lost 0.5%. The action was stronger in the bond market, where Treasury yields eased after a report showed inflation ticked up by less last month than economists expected. That raised expectations for the Federal Reserve to cut interest rates later this year. Markets didn't react much to the conclusion of two days of trade talks between the U.S. and China.
THIS IS A BREAKING NEWS UPDATE. AP's earlier story follows below.
NEW YORK (AP) — Wall Street's rally is stalling on Wednesday after U.S. stocks climbed back within 2% of their all-time high.
The S&P 500 was 0.4% lower in late trading and on track for its first drop in four days. The Dow Jones Industrial Average was down 45 points, or 0.1%, with roughly an hour remaining in trading, and the Nasdaq composite was 0.6% lower.
Several Big Tech stocks led the way lower, and a 1.9% drop for Apple was the heaviest weight on the market. It's been listless this week after unveiling several modest upcoming changes to the software that runs its devices.
The action was stronger in the bond market, where Treasury yields eased after a report suggested President Donald Trump's tariffs are not pushing inflation much higher, at least not yet. U.S. consumers had to pay prices that were 2.4% higher overall in May than a year earlier. That was up from April's 2.3% inflation rate, but it wasn't as bad as the 2.5% that Wall Street was expecting.
A fear has been that Trump's wide-ranging tariffs could ignite another acceleration in inflation, just when it had seemed to get nearly all the way back to the Federal Reserve's 2% target from more than 9% at its peak three summers ago.
It hasn't happened, though economists warn it may take months more to feel the full effect of Trump's tariffs. For the time being, many businesses may be pulling products they already had in their inventories rather than passing along higher costs from fresh imports.
'Another month goes by with little evidence of tariffs, but the longer-term inflation challenge they pose remain,' according to Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management.
Financial markets also had only modest reactions to the conclusion of two days of trade talks between the United States and China in London.
Trump said Wednesday that China will supply rare-earth minerals and magnets to the United States, while his government will allow Chinese students into U.S. universities in a deal that still needs an agreement by him and by China's leader. Trump also said that 'President XI and I are going to work closely together to open up China to American Trade. This would be a great WIN for both countries!!!'
Investors are still hoping for a more sweeping trade deal that would ease tensions between the world's two largest economies.
Hopes for such deals between the United States and countries around the world have been one of the main reasons the S&P 500 has charged nearly all the way back to its all-time high after dropping roughly 20% below a couple months ago. Without them, the fear is that Trump's high tariffs could drive the economy into a recession while pushing inflation higher. The S&P 500 is sitting 2.1% below its record.
On Wall Street, Chewy dropped 12.5% after the seller of pet supplies reported a weaker profit for the latest quarter than analysts had forecast. Expectations were high after its stock had already rallied nearly 37% coming into the day for the year so far.
Tesla swung from a gain in the morning to a loss of 0.4% to continue its shaky run. It's been recovering much of its big losses taken last week after Elon Musk's relationship with Trump imploded, which in turn raised fears about a loss of business for the electric-vehicle company. Musk on Wednesday backed away from some of his earlier comments and said they went 'too far.'
In the bond market, the yield on the 10-year Treasury eased to 4.41% from 4.47% late Tuesday. Shorter-term yields, which more closely track expectations for what the Fed will do with overnight interest rates, fell more.
Wednesday's better-than-expected reading on inflation raised expectations along Wall Street that the Fed could cut its main interest rate at least twice by the end of the year.
The Fed has been keeping interest rates steady so far this year, going on pause after cutting rates at the end of last year. It has been waiting to see how much Trump's tariffs raise inflation because cutting interest rates could push inflation up even more, as they give the economy a boost.
'The Fed could be justified in doing some preemptive rate cuts,' said Brian Jacobsen, chief economist at Annex Wealth Management. 'They were afraid that inflation would rise before growth would slow, but the script has been flipped and they will likely change their tune.'
In stock markets abroad, indexes fell across much of Europe and rose in Asia. South Korea's Kospi was one of the best performers and jumped 1.2%.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
38 minutes ago
- Globe and Mail
Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR
According to a recent report by Coherent Market Insights, the global Health Data Interoperability Market is estimated to be valued at USD 84.58 billion in 2025 and is expected to reach USD 352.13 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.65% from 2025 to 2032. The strong growth of the market is driven by the rising demand for seamless data exchange among healthcare providers, the pursuit of enhanced patient care, and the growing adoption of electronic health records (EHRs) and other digital health technologies. Global Health Data Interoperability Market Key Takeaways According to Coherent Market Insights (CMI), the global health data operability care market size is projected to grow more than 4.1X, increasing from USD 84.58 Bn in 2025 to USD 352.13 Bn by 2032, at a CAGR of 22.65%. By deployment model, cloud-based segment is expected to account for nearly two-thirds of the global health data interoperability market share in 2025. Based on component, software category is anticipated to generate a market revenue of about USD 45.92 Bn in 2025. By type, electronic health records (EHRs) segment will likely account for more than two-fifths of the global market revenue share by 2025. North America is expected to retain its monopoly in the global market due to increasing adoption of digital health technologies. As per Coherent Market Insights' latest health data interoperability market research, North America will hold nearly 2/5 of the global market share in 2025. Asia Pacific health data interoperability market is estimated to be valued at around USD 25.62 Bn in 2025. Growing Adoption of Electronic Health Records (EHRs) Boosting Market Growth Coherent Market Insights' new health data interoperability market analysis offers insights into prominent factors driving industry growth. Increasing adoption of electronic health records (EHRs) is one key growth driver. In the contemporary world, more and more hospitals and clinics are embracing electronic health records. For instance, as per the National Center for Health Statistics, about 88.2% of office-based physicians in the United States use an EMR/EHR system. High adoption of EHRs is creating an urgent need for seamless data exchange across various healthcare systems. This will drive demand for health data interoperability solutions during the forecast period. High Implementation Cost and Lack of Standardization Limiting Market Growth The future health data interoperability market outlook looks promising. However, lack of universal standards and high implementation costs are expected to restrain market growth to some extent. Different healthcare providers often use disparate EHR systems, making seamless data exchange challenging. Absence of universally accepted interoperability standards across regions can hinder consistent integration and data sharing, negatively affecting the health data interoperability market growth. Implementing interoperable systems requires substantial investments in both infrastructure and software. This deters smaller clinics and healthcare providers, especially across underserved regions, from opting for these systems, thereby reducing the health data interoperability market demand. Purchase Now Up to 25% Discount on This Premium Research Report: Rapid Shift Towards Value-Based Care to Create Lucrative Growth Avenues Growing adoption of value-based care (VBC) models is driving demand for improved patient outcomes and cost efficiency across healthcare systems. This transition necessitates seamless health data interoperability to enable coordinated care as well as real-time data exchange and performance measurement. As a result, the shift towards VBC is unlocking significant growth opportunities for health data interoperability companies. Policies like HITECH Act and EU GDPR mandate interoperability as well as patient access to data. They will also create lucrative growth prospects for health data interoperability solution providers in the coming years. Policies like the HITECH Act and the EU GDPR emphasize interoperability as well as patient access to health data. These regulations are expected to drive demand for health data interoperability solutions, creating lucrative growth opportunities for industry players. Impact of AI on the Health Data Interoperability Market AI is revolutionizing the health data interoperability industry by tackling long-standing challenges like fragmented data and inconsistent data standards. Organizations use machine learning and NLP to automate data mapping, convert unstructured records into structured formats, and streamline EHR integration. AI-driven predictive analytics can forecast data exchange needs, enhance real‑time clinical workflows, and reduce clinical errors. Federated learning frameworks allow AI models to train across multiple organizations without moving sensitive patient data, which improves privacy and fosters collaboration. AI-powered interoperability solutions are gaining immense traction in the modern healthcare ecosystem. This is due to their potential to boost operational efficiency, enable personalized care, reduce costs, and accelerate the transition towards value‑based models. Emerging Health Data Interoperability Market Trends Rising demand for patient-centric care is a key growth-shaping trend in the market. Today, patients want access to their health information through mobile apps and patient portals. This is creating a need for connected systems. Growing popularity of cloud-based interoperability solutions is expected to boost the overall health data interoperability market value. These scalable and cost-effective platforms are gradually replacing on-premise systems across various regions. Rise of telehealth services and adoption of remote patient monitoring devices are also positively impacting the health data interoperability market growth. These technologies require robust interoperability solutions to ensure seamless data flow between patients, healthcare providers, and monitoring platforms. Analyst's View 'The global health data interoperability market is poised to exhibit robust growth, owing to increasing government mandates and regulatory frameworks, widespread adoption of electronic health and medical record systems (EHR/EMR), and a growing emphasis on value-based care models,' said senior analyst Komal Dighe. Current Events and Their Impact on the Health Data Interoperability Market Event Description and Impact U.S. HTI-1 Final Rule Description: U.S. HTI-1 Final Rule enforces FHIR-based standards for certified health IT systems. Impact: This drives adoption of compliant interoperability platforms and APIs, leading to market growth. EU's European Health Data Space (EHDS) Rollout Description: European Union's EHDS initiative, officially implemented in 2025, requires member states to adopt standardized cross-border health data sharing through unified interoperability frameworks. Impact: This is driving health IT vendors to comply with EHDS standards as well as boosting demand for FHIR-based platforms and multilingual data exchange solutions. Competitor Insights Key companies in health data interoperability market report include: - Cerner Corporation - Epic Systems Corporation - Meditech - Allscripts Healthcare Solutions - athenahealth - InterSystems Corporation - Philips Healthcare - GE Healthcare - Oracle Health Sciences - NextGen Healthcare - IBM Watson Health - Microsoft Health - McKesson Corporation - Siemens Healthineers - Infor Healthcare Key Developments In March 2025, 1upHealth sets a new benchmark for health data interoperability with the launch of its new 1up Platform. The new platform, built on a modern lakehouse architecture, is designed to deliver 'Health Data On Demand'. It offers real-time data access, scalable management, and advanced analytics to help healthcare organizations enhance operational efficiency, care quality, and patient outcomes. In March 2025, Epic Systems Corporation unveiled industry-leading Genomics, AI, and interoperability solutions at the HIMSS 2025 Conference. These new solutions are designed to help healthcare organizations advance in rapidly evolving environment. They have the potential to enhance clinical care, streamline operations, and foster more personalized patient treatments. In January 2025, MEDITECH unveiled its new set of APIs fully compatible with version 4 of the United States Core Data for Interoperability (USCDI v4). This new launch highlights the company's leadership in advancing standards-based interoperability across healthcare systems. Market Segmentation Deployment Model Insights Cloud-Based On-Premises Component Insights Hardware Software Services Type Insights Electronic Health Records (EHR) Health Information Exchange (HIE) Interoperability Solutions Integration Platforms Interoperability Level Insights Foundational Interoperability Structural Interoperability Semantic Interoperability End User Insights Healthcare Providers Healthcare Payers Pharmaceutical Companies Research Institutions Regional Insights North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa § Central Africa Get Customization on this Report: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Raj Shah Email: Send Email Phone: +1-252-477-1362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States City: Burlingame State: California Country: United States Website:


Globe and Mail
an hour ago
- Globe and Mail
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
[content-module:CompanyOverview|NASDAQ:TSLA] When a stock climbs 14% in just two trading sessions despite getting hit with not one but two analyst downgrades, the market is sending a clear message. Tesla Inc (NASDAQ: TSLA) has done exactly that this week, shrugging off downgrades from both Baird and Argus Research as if they were minor speed bumps on a highway. For growth-focused investors, this apparent disconnect between Wall Street caution and actual market action represents something we love to see and write about: a buying opportunity. The Downgrades That Missed the Mark Monday brought a double dose of analyst pessimism when Baird cut Tesla from Buy to Hold, followed by Argus Research, who made the same move. Both firms cited the same primary concern: the very recent and very public spat between Elon Musk and President Trump, which they believe introduces significant uncertainty to Tesla's prospects. Baird's team also expressed particular skepticism about management's optimistic robotaxi timeline and suggested that positive expectations around the upcoming affordable vehicle launch, which we highlighted last week, might already be baked into the current share price. Meanwhile, Argus focused heavily on how the Musk-Trump dispute could weaken demand, especially as EV tax credits face potential expiration. They warned that Tesla's stock now appears driven more by non-fundamental events than actual business performance. Market Defiance Tells the Real Story But here's what makes Tesla so compelling as a stock to own: Tesla shares have actually gained 14% this week already, suggesting investors are treating the analyst caution as temporary noise rather than a very red warning sign. The stock's ability to climb despite fresh negative coverage indicates that the market sees through the political theater the underlying business momentum and long-term potential. After all, Tesla had posted what analysts called a fundamentally poor quarter in April, yet shares had already begun recovering before the Trump-Musk tensions erupted. That recovery trajectory appears to be reasserting itself regardless of Wall Street's newfound caution. The Bullish Chorus Remains Intact [content-module:Forecast|NASDAQ:TSLA] While Baird and Argus stepped to the sidelines, the broader analyst community tells a different story and is worth noting. The team at Piper Sandler actually reiterated their Overweight rating on Tuesday, echoing the updates from Morgan Stanley and Wedbush this month, already in maintaining bullish stances. Wedbush has been particularly aggressive, slapping a $500 price target on the stock and standing firm despite the recent volatility. This split in analyst opinion actually strengthens the contrarian case. When selective downgrades occur against a backdrop of maintained Buy ratings from other respected firms, it often signals that the negative factors are temporary rather than structural. Case in point: the fact that these downgrades focus primarily on political uncertainty rather than fundamental business deterioration supports this view. Perfect Storm for Patient Capital Tesla's current situation creates an almost textbook setup for contrarian investors. The stock has already absorbed a 25% hit from political noise, endured two high-profile downgrades, and still managed to surge 14% in just two sessions. This combination suggests that temporary headwinds are actually creating opportunity rather than risk. Consider this: if Tesla can gain 14% while dealing with two rare analyst downgrades and political uncertainty, imagine the potential upside once these temporary factors fade. The upcoming affordable vehicle launch and robotaxi development remain on track regardless of Washington drama, and Tesla's core EV market position continues to strengthen globally. For investors who believe in Tesla's long-term transformation story, the current moment offers something increasingly scarce: the chance to buy into a high-growth stock at a potential discount. The Window Is Already Narrowing All that being said, the market's quick dismissal of Monday's downgrades suggests this buying opportunity may be short-lived. Political tensions have a way of resolving themselves, especially when business interests are at stake. Meanwhile, Tesla's product roadmap and market expansion continue regardless of Twitter feuds or analyst hand-wringing. For investors willing to look past the headline noise, these rare downgrades may prove to be perfectly timed entry points rather than warning signals. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...


Globe and Mail
an hour ago
- Globe and Mail
Crude Prices Slip as Dollar Strength Sparks Long Liquidation
July WTI crude oil (CLN25) Tuesday closed down -0.31 (-0.47%), and July RBOB gasoline (RBN25) closed down -0.0072 (-0.34%). Crude oil and gasoline prices on Tuesday gave up an early advance and settled lower. Dollar strength (DXY00) on Tuesday sparked long liquidation pressures in crude oil, causing prices to retreat. Crude oil and gasoline initially moved higher Tuesday, with crude posting a 2-1/4 month high and gasoline posting a 2-week high. Signs of progress in US-China trade talks supported crude oil prices. Also, Tuesday's rally in the S&P 500 to a 3-1/2 month high shows confidence in the economic outlook that is supportive of energy demand and crude prices. The possibility of reduced trade tensions between the US and China is positive for economic growth and energy demand. US Commerce Secretary Lutnick said Tuesday that Monday's initial trade talks with China have been "fruitful." The trade negotiations continued Tuesday in London. Reduced oil production in Canada is bullish for crude prices, as wildfires in Alberta, Canada, have shut down nearly 350,000 barrels per day (bpd) of crude production, or approximately 7% of Canada's total output. The World Bank on Tuesday cut its 2025 global GDP forecast to +2.3% from a +2.7% estimate in January, which was negative for energy demand and crude prices. Crude prices were undercut last Wednesday after Bloomberg reported that Saudi Arabia is open to additional crude production hikes in a bid to increase its market share. The report stated that Saudi Arabia wants OPEC+ to increase crude output by 411,000 bpd in August and potentially in September to capitalize on peak summer demand. Signs of a global oil supply glut are weighing on crude prices, as crude oil inventories have risen by 170 million barrels over the past 100 days, according to Kayrros, which monitors inventories. An increase in crude oil held worldwide on tankers is bearish for oil prices. Vortexa reported Monday that crude oil stored on tankers that have been stationary for at least seven days rose by +9.1% w/w to 81.83 million bbl in the week ended June 6. Concern about a global oil glut is negative for crude prices. On May 31, OPEC+ agreed to a 411,000 bpd crude production hike for July after raising output by the same amount for June. Saudi Arabia has signaled that additional similar-sized increases in crude output could follow, which is viewed as a strategy to reduce oil prices and punish overproducing OPEC+ members, such as Kazakhstan and Iraq. OPEC+ is boosting output to reverse the 2-year-long production cut, gradually restoring a total of 2.2 million bpd of production. OPEC+ had previously planned to restore production between January and late 2025, but now that production cut won't be fully restored until September 2026. OPEC May crude production rose +200,000 bpd to 27.54 million bpd. Doubts about a nuclear deal between Iran and the US supported crude oil prices. Iranian Supreme Leader Ali Khamenei recently said that he doesn't think negotiations with the US will succeed, and he urged the Trump administration to stop "talking nonsense." President Trump recently said Iran will face "something bad" if it doesn't quickly accept a US proposal over its nuclear program. The consensus is that Wednesday's weekly EIA crude inventories will fall by -2.6 million, and gasoline supplies will climb by +750,000 bbl. Last Wednesday's EIA report showed that (1) US crude oil inventories as of May 30 were -7.0% below the seasonal 5-year average, (2) gasoline inventories were -1.6% below the seasonal 5-year average, and (3) distillate inventories were -17.2% below the 5-year seasonal average. US crude oil production in the week ending May 30 rose +0.1% w/w at 13.408 million bpd, modestly below the record high of 13.631 million bpd from the week of December 6. Baker Hughes reported last Friday that active US oil rigs in the week ending June 6 fell by -9 to a 3-1/2 year low of 442 rigs. The number of US oil rigs has fallen over the past two years from the 5-year high of 627 rigs posted in December 2022.